---
title: "Nasdaq Warns Abpro Holdings of Possible Delisting Over Board Compliance Lapses"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275658950.md"
description: "Abpro Holdings Inc. is at risk of being delisted from the Nasdaq due to noncompliance with Listing Rules after two board members resigned. The company fails to meet requirements for board independence, including having a majority of independent directors and minimum independent members on key committees. Although its stock remains listed for now, the Nasdaq Hearings Panel is reviewing the situation. Abpro is working to appoint qualified independent directors to regain compliance."
datetime: "2026-02-11T21:17:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275658950.md)
  - [en](https://longbridge.com/en/news/275658950.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275658950.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275658950.md) | [繁體中文](https://longbridge.com/zh-HK/news/275658950.md)


# Nasdaq Warns Abpro Holdings of Possible Delisting Over Board Compliance Lapses

Abpro Holdings Inc. is facing potential delisting from the Nasdaq Stock Market due to noncompliance with several Nasdaq Listing Rules following the recent resignations of two board members. The company no longer meets requirements for board and committee independence, including rules mandating a majority of independent directors and minimum independent membership on the audit and compensation committees. While the company’s stock remains listed for now, the Nasdaq Hearings Panel will consider these deficiencies in its ongoing review of Abpro’s continued listing. The company is working to appoint qualified independent directors to restore compliance within the required timeframes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-014903), on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Abpro Holdings, Inc. (ABP.US)](https://longbridge.com/en/quote/ABP.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Abpro Holdings, Inc. (ABPO.US)](https://longbridge.com/en/quote/ABPO.US.md)

## Related News & Research

- [What is HC Wainwright's Estimate for KROS FY2030 Earnings?](https://longbridge.com/en/news/278112283.md)
- [Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M](https://longbridge.com/en/news/277812097.md)
- [Bluejay Diagnostics FY2025 net loss narrows 11% to $6.85 million as interest expense plunges 100% to $0 million](https://longbridge.com/en/news/278165187.md)
- [Caribou Biosciences Q4 licensing revenue rises, net loss narrows](https://longbridge.com/en/news/277986902.md)
- [Mangoceuticals Reports Zero Respiratory-Related Mortality in 29,000-Bird MGX-0024 Trials](https://longbridge.com/en/news/278164774.md)